Interesting data are emerging from the Indian weight-loss drug market this March. Mounjaro, containing the molecule tirzepatide, Eli Lilly’s weight-loss drug, appears to be losing some ground as ...

As Asia grappled with the impact of the Iran war, a major pharmaceutical milestone quietly made the headlines. On March 20, the patent for semaglutide, the active ingredient in Novo Nordisk’s Ozempic ...

Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. REUTERS/Hollie Adams March 31 (Reuters) - Novo Nordisk on Tuesday cut the prices of its ...

Two-time cancer survivor Sherman McDaniel may be in fragile health, but she is sticking to her vow: “I’m not going anywhere until Generic Theater has a permanent home. Until then, I will not die.” ...

A Canadian pharmaceutical company, headed by two former executives with the company behind Ozempic, hopes to make a generic version of the weight-loss drug in Edmonton. Data protections on the GLP-1 ...

The blockbuster weight loss drug sold as Ozempic and Wegovy will soon go generic in countries that are home to 40% of the world’s population, significantly lowering the price of a costly medicine that ...

With patents expiring today in India for Novo Nordisk’s popular diabetes and obesity drugs Ozempic and Wegovy, more than 40 generic drug makers are expected to begin launching their cheaper versions ...

The simultaneous patent expiry of Ozempic’s active ingredient in China and India on Friday is a watershed moment. Until now, the revolutionary weight-loss drugs have been available largely to people ...

In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions. By Rebecca ...

Persistent shortages (216 active at end‑2025) impose major operational costs (~$900M labor/year) and hit oncology, anesthesia, and emergency care, forcing substitutions and compounding with safety and ...

To learn more about the CNBC CFO Council, visit cnbccouncils.com/cfo Nearly half of U.S. generic prescriptions originate in India, which relies on the Strait of ...

Inhaled corticosteroid–long-acting beta-agonist (ICS-LABA) inhalers are widely prescribed for asthma and chronic obstructive pulmonary disease. ICS-LABAs are largely interchangeable within the class; ...